About Jim Breyer
Jim Breyer, founder and CEO of Breyer Capital, has been active in discussions about artificial intelligence, healthcare, and technology investing. In a July 2025 interview, he stated that AI is "fundamental to almost everything that we'll see and do" and described having made about 15 investments in AI and health, spanning diagnosis, preventive care, and drug discovery. He said his approach involves identifying Nobel laureates or potential Nobel laureates in medicine and pairing them with AI talent from companies like Google, Meta, and Microsoft. Breyer also commented on the Stargate Project, a $500 billion AI infrastructure initiative, calling it "too big, too expensive" and giving it a 9.5 out of 10 on a difficulty scale, while noting that capital expenditure projects of that scale "tend to not work."
Breyer has also discussed his investment in Circle, the stablecoin company, which went public in 2025. He said he invested in 2013 after meeting with co-founders Jeremy Allaire and Sean Neville, describing his cost basis as $0.27 per share. He noted that regulatory challenges were always a risk but that Allaire had "a sense of wanting to be regulated in the right way." Regarding Meta, Breyer said in early 2025 that he sees a "revitalized Mark Zuckerberg" and that the company is "as well positioned in AI as anyone out there." He has also expressed optimism about Nvidia and AMD, stating that Nvidia is "unstoppable" over a three-year timeframe and that he would add AMD to the list of "Magnificent Seven" stocks.
Source: AI-verified profile updated from Jim Breyer's recent appearances.
Browse all interviews →
Transcript (16 segments)
I
Interviewer0:00
Take a look at shares of Circle, absolutely on a tear up more than 250% since the company made its market debut here at the NYSE yesterday. Momentous occasion for our next guest, who is the company's largest individual shareholder, joining us in a CNBC exclusive here at post nine is Breyer Capital founder and CEO Jim Breyer. Welcome back. It's great to have you.
J
Jim Breyer0:26
It's great to be with you, Sarah and Karl.
I
Interviewer0:28
And congratulations on this debut. Take us back. What was it, 2013 when you met?
J
Jim Breyer0:35
It was 2013, but I met Jeremy when I was an investor in Macromedia, and we bought his first company in 2000. And then I invested in Jeremy in his next startup called Brightcove, which we went public, stayed very close touch with Jeremy. And Jeremy and Sean in 2013 called me and said we have an idea about the future of money. And so we walked through Harvard Yard. After two hours, I shook hands with both of them and said, I'm in.
I
Interviewer1:10
So was it because you invest in people? I love your story about when you invested in Mark Zuckerberg when he was very young, before anybody else, 20 years old. So the people or the concept, because no one was talking about stablecoins back then?
J
Jim Breyer1:24
It's always both. So people, people, people, you try to get the best people and the best neighborhoods. If I use a real estate analogy that we often speak about at Blackstone and elsewhere, Jeremy has great courage. I've been able to watch him. Perseverance hires extraordinarily well. Sean is a great part of the Circle story. He's exceptional. And so it's always about how big is a potential market and how tremendous are the entrepreneurs and founders in terms of vision, tenacity, and a lot of it's gut instinct. When I walk away, sometimes I spend a couple of days, sometimes a couple of weeks on due diligence. And in some cases, I don't want the meeting to end without shaking hands on the deal.
I
Interviewer2:20
Cost basis on Circle, $0.27. Not bad. And at the time you had, what was your view on whether policymakers would join you in this story? Because that's part of it too, is it not?
J
Jim Breyer2:33
It always was a huge risk. It's always a big risk. Even as we speak today, I knew there would be regulatory challenges for sure in 2013. That's true with many of the health care AI companies I invest in where I know even on an emergency FDA fast track, regulatory will play a role. But again, I felt that Jeremy in particular had a sense of wanting to be regulated in the right way. And it's turned out Jeremy, Sean, the entire team at Circle, I'm so happy for them, really have been extraordinarily thoughtful.
I
Interviewer3:14
Well, it's gone up a lot. I don't know, were you a seller at all?
I
Interviewer3:19
Say anything. Okay. So it's now almost $20 billion market cap company. How do you value a company like this? Does it still offer value for investors who weren't as lucky as you to get in so early?
J
Jim Breyer3:32
I'll look backwards. There are certain topics I'll stay away from, of course, but the market itself for stablecoins is enormous. And again, Jeremy, Sean, the team we've hired is really exceptional. And how this plays out, we shall see. But it's very typical of the kinds of new startup investments that Breyer Capital loves: a phenomenal team, a team that really thinks thoughtfully about iterating, reiterating on a process very quickly. Mark Zuckerberg perhaps being the best I've ever seen at iteration daily on how to build a business model.
I
Interviewer4:16
Who's the next one? The next Mark Zuckerberg?
J
Jim Breyer4:18
The next Mark Zuckerberg or the next Michael Dell. I could go on and on.
I
Interviewer4:23
But any phenomenal companies that are going to go public that you would be excited about?
J
Jim Breyer4:28
There are a couple companies. A third time entrepreneur, Daniel Nadler, who has built a company called Open Evidence, has that potential, and they've recently raised money from a number of top tier Silicon Valley firms that are good friends. In many cases, Daniel's company is basically using AI to go through all the medical journals in the world and provide that information at the point of care for doctors, and approximately 25% of the doctors in the United States use it.
